Hanley, Michael J. http://orcid.org/0000-0001-9266-2797
Kerstein, David
Tugnait, Meera http://orcid.org/0000-0002-9005-375X
Narasimhan, Narayana
Marbury, Thomas C. http://orcid.org/0000-0002-6416-3314
Venkatakrishnan, Karthik http://orcid.org/0000-0003-4039-9813
Gupta, Neeraj http://orcid.org/0000-0002-5500-5218
Funding for this research was provided by:
ARIAD Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 20 December 2022
Accepted: 8 February 2023
First Online: 13 April 2023
Declarations
:
: Approval for this study was obtained from the institutional review board of the study site (Orlando Clinical Research Center, Orlando, FL). This study was conducted in accordance with current Good Clinical Practice, the Declaration of Helsinki, the International Council for Harmonisation guidelines, and all applicable regulatory requirements.
: All participants provided written informed consent.
: MJH is an employee of Takeda Development Center Americas, Inc., Lexington, MA, USA. DK, MT, NN, and KV are former employees of Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. TCM is an employee and equity owner of Orlando Clinical Research Center. NG is an employee of Takeda Development Center Americas, Inc., Lexington, MA, USA.